Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $164.01 million. The enterprise value is $167.07 million.
| Market Cap | 164.01M |
| Enterprise Value | 167.07M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 24.23 million shares outstanding. The number of shares has increased by 23.90% in one year.
| Current Share Class | 24.23M |
| Shares Outstanding | 24.23M |
| Shares Change (YoY) | +23.90% |
| Shares Change (QoQ) | +1.30% |
| Owned by Insiders (%) | 18.49% |
| Owned by Institutions (%) | 44.16% |
| Float | 13.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.31 |
| Forward PS | 2.14 |
| PB Ratio | 13.15 |
| P/TBV Ratio | 13.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.18, with a Debt / Equity ratio of 2.26.
| Current Ratio | 3.18 |
| Quick Ratio | 2.75 |
| Debt / Equity | 2.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financial Efficiency
Return on equity (ROE) is -113.82% and return on invested capital (ROIC) is -19.16%.
| Return on Equity (ROE) | -113.82% |
| Return on Assets (ROA) | -14.92% |
| Return on Invested Capital (ROIC) | -19.16% |
| Return on Capital Employed (ROCE) | -34.33% |
| Weighted Average Cost of Capital (WACC) | 15.28% |
| Revenue Per Employee | $323,282 |
| Profits Per Employee | -$86,014 |
| Employee Count | 220 |
| Asset Turnover | 1.29 |
| Inventory Turnover | 7.45 |
Taxes
In the past 12 months, Exagen has paid $50,000 in taxes.
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.41% in the last 52 weeks. The beta is 2.03, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 2.03 |
| 52-Week Price Change | -26.41% |
| 50-Day Moving Average | 4.79 |
| 200-Day Moving Average | 5.08 |
| Relative Strength Index (RSI) | 72.16 |
| Average Volume (20 Days) | 413,896 |
Short Selling Information
The latest short interest is 978,980, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 978,980 |
| Short Previous Month | 813,368 |
| Short % of Shares Out | 4.04% |
| Short % of Float | 7.18% |
| Short Ratio (days to cover) | 4.32 |
Income Statement
In the last 12 months, Exagen had revenue of $71.12 million and -$18.92 million in losses. Loss per share was -$0.80.
| Revenue | 71.12M |
| Gross Profit | 41.70M |
| Operating Income | -13.21M |
| Pretax Income | -18.87M |
| Net Income | -18.92M |
| EBITDA | -10.77M |
| EBIT | -13.21M |
| Loss Per Share | -$0.80 |
Balance Sheet
The company has $24.59 million in cash and $27.66 million in debt, with a net cash position of -$3.07 million or -$0.13 per share.
| Cash & Cash Equivalents | 24.59M |
| Total Debt | 27.66M |
| Net Cash | -3.07M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 12.22M |
| Book Value Per Share | 0.50 |
| Working Capital | 29.40M |
Cash Flow
In the last 12 months, operating cash flow was -$6.50 million and capital expenditures -$1.09 million, giving a free cash flow of -$7.59 million.
| Operating Cash Flow | -6.50M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 2.44M |
| Net Borrowing | -1.41M |
| Free Cash Flow | -7.59M |
| FCF Per Share | -$0.31 |
Margins
Gross margin is 58.64%, with operating and profit margins of -18.58% and -26.61%.
| Gross Margin | 58.64% |
| Operating Margin | -18.58% |
| Pretax Margin | -26.54% |
| Profit Margin | -26.61% |
| EBITDA Margin | -15.15% |
| EBIT Margin | -18.58% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.90% |
| Shareholder Yield | -23.90% |
| Earnings Yield | -11.54% |
| FCF Yield | -4.63% |
Analyst Forecast
The average price target for Exagen is $9.86, which is 45.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.86 |
| Price Target Difference | 45.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 11.37% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -5.26 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.26 |
| Piotroski F-Score | 2 |